Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C129689
http://purl.obolibrary.org/obo/NCIT_C129689
Preferred Name

Palupiprant
Definitions
An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.
label
Palupiprant
prefLabel
Palupiprant
in_subset
Preferred_Name
Palupiprant
Is_Value_For_GDC_Property
Display_Name
Palupiprant
Maps_To
Prostaglandin E2 EP4 Receptor Inhibitor E7046
Prostaglandin E2 EP4 Receptor Inhibitor AN0025
PDQ_Open_Trial_Search_ID
792739
Has_Target
FDA_UNII_Code
YWY620GU8I
prefixIRI
NCIT:C129689
NCI_Drug_Dictionary_ID
792739
Contributing_Source
CTRP
FDA
subClassOf
code
C129689
type
PDQ_Closed_Trial_Search_ID
792739
Semantic_Type
Pharmacologic Substance
CAS_Registry
1369489-71-3
NCI_META_CUI
CL507851
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display